Tony Coles takes sec­ond neu­ro­science start­up pub­lic as Yu­man­i­ty re­verse merges

5 years ago
Deals

Which big bio­phar­ma play­er should gam­ble $34B on a ripe rare-dis­ease M&A tar­get? An ac­tion-hun­gry top an­a­lyst fills ...

5 years ago
Deals

Dri­ving to the $278M mark on rais­es, a leg­endary R&D ex­pert sets his sights on an­oth­er piv­otal goal line

5 years ago
People
Financing

Take­da gets a $2.2B deal for its OTC unit as debt-re­lief dri­ve nears its end

5 years ago
Deals

No­var­tis’ PD-(L)1 catch-up at­tempt stum­bles in PhI­II

5 years ago
R&D

Covid-19 roundup: No­vavax be­gins PhII tri­al in US and Aus­tralia; As­traZeneca signs US man­u­fac­tur­ing deal with ...

5 years ago
Coronavirus

Trump her­alds a 'his­toric break­through' in the R&D fight against Covid-19 — now comes the in­stant back­lash as the ...

5 years ago
FDA+
Coronavirus

The lead­ers in the race to de­vel­op a Covid-19 vac­cine say they could have piv­otal da­ta in Oc­to­ber — but Trump ...

5 years ago
Bioregnum
Coronavirus

J&J adds yet an­oth­er mul­ti­ple myelo­ma reg­i­men to the Darza­lex la­bel as Sanofi ri­val jumps in

5 years ago
R&D
FDA+

Lil­ly Asia Ven­tures leads As­traZeneca spin­out's $100M push in­to Chi­na's grow­ing R&D hub in Wuxi

5 years ago
Financing
China

Bio­Marin sub­mits NDA for con­tro­ver­sial achon­dropla­sia drug; Cell and gene ther­a­py boom sparks €49M buy­out

5 years ago
News Briefing

How big is the 2020 biotech IPO boom? More than $11 bil­lion big among the year's four dozen en­trants

5 years ago
Financing

MD An­der­son­'s Patrick Hwu to helm Mof­fitt Can­cer Cen­ter; Af­ter Rock­well Med­ical ouster, Robert Chioi­ni gets an­oth­er ...

5 years ago
Peer Review

Phar­ma gi­ants back a leader in vir­tu­al clin­i­cal tri­als as Covid-19 blights sites

5 years ago
Financing

Covid-19 roundup: J&J plans 60,000-per­son PhI­II for Sep­tem­ber; Pe­ter Marks draws a red line

5 years ago
Coronavirus

That new biotech com­pound Arie Bellde­grun & Co. have been build­ing in Sea­port? It turns out one fast-grow­ing ...

5 years ago
Pharma

Kymera, rais­ing $173M+, be­comes the 48th biotech IPO of the year as 2020 sur­pass­es 2019

5 years ago
Financing

De­railed gene ther­a­py study re­ports 3rd death as safe­ty and dura­bil­i­ty is­sues cloud a boom­ing field

5 years ago
R&D
Cell/Gene Tx

No­var­tis gets the green light to start mar­ket­ing its next prospec­tive block­buster. And they're charg­ing a pre­mi­um for ...

5 years ago
R&D
FDA+

Ron Evans steals a trick from I/O, and points the way to a trans­for­ma­tion­al di­a­betes ther­a­py

5 years ago
Discovery

Watch out Bris­tol My­ers, Mer­ck is right on your heels with more pos­i­tive Keytru­da da­ta to take to the FDA

5 years ago
R&D

Eli Lil­ly part­ner Ab­Cellera ac­quires bis­pe­cif­ic plat­form; Te­va faces more law­suits, this time over opi­oid mar­ket­ing

5 years ago
News Briefing

Is Take­da’s post-Shire sell-off ap­proach­ing its fi­nal days?

5 years ago
Deals

Sev­en PD-(L)1 play­ers could be vy­ing for a place on Chi­na's drug re­im­burse­ment list. How far will they go?

5 years ago
China
Pharma
First page Previous page 809810811812813814815 Next page Last page
A service from the Financial Times